PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
← catalyst calendarNCT06750432 · readout ≤ 133 d
Sponsored by ProMis Neurosciences, Inc (industry) · PMN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
144actual
Sites
22
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-13 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer Disease, Early Onset
Interventions
- Drug: PMN310
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of PMN310 following repeat intravenous infusions of PMN310
measured Up to Day 337
Biomarker response to PMN310 following repeat intravenous infusions of PMN310
measured Up to Day 337
Safety and tolerability of PMN310 following repeat intravenous infusions of PMN310
measured Up to Day 337
Permalink · PMN's whole pipeline · Catalyst calendar · Every registered study · What changed